China’s public healthcare service payer, the National Healthcare Security Administration (NHSA), kept the level of drug price cuts steady at an average of roughly 60% in its latest round of annual negotiations for innovative products included in the new version of the National Reimbursement Drug List (NRDL), the agency disclosed on 18 January.
Although state negotiators remained unrelenting in the pursuit of deep discounts in return for inclusion in the 2022 round, which was delayed from December to early this year due to spiking COVID-19 cases, the number of novel medicines to be added to the list on 1 March grew 36% to 91 versus 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?